SOLAZYME INC 4
4 · SOLAZYME INC · Filed Mar 11, 2015
Insider Transaction Report
Form 4
SOLAZYME INCSZYM
Licari Peter
EVP, Research & Development
Transactions
- Sale
Common Stock
2015-03-09$2.69/sh−19,062$51,359→ 175,529 total
Footnotes (2)
- [F1]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan and were mainly to cover tax withholding obligations in connection with the vesting of restricted stock units that occurred on or shortly before the date of sale.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.56 to $2.79, inclusive. The reporting person undertakes to provide to Solazyme, Inc., any security holder of Solazyme, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.